Form 10 Explorer
10-Q
Quarterly Report
Actuate Therapeutics, Inc.

ACTU

NASDAQ

CIK: 1652935

File #: 001-42139

Period End: Mar 31, 2025

Fiscal Year: 2025

View on EDGAR
Balance Sheet
31 line items · 2 periods
XBRL
ItemMar 31, 2025Dec 31, 2024
ASSETS
Current assets:
Cash and Cash Equivalents
3,889,4058,641,622
Other Non-Operating Current Assets
359,159566,278
Total current assets
4,248,5649,207,900
Other Non-Operating Non-Current Assets
234,475110,548
Total assets
4,483,0399,318,448
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts Payable
2,644,3491,921,189
Other Non-Operating Current Liabilities
5,200,7625,921,908
Other Current Liabilities
1,237,886888,449
Other Non-Operating Current Liabilities
70,95770,957
UIC License Agreement
70,95770,957
Total current liabilities
9,153,9548,802,503
Long term liabilities:
Other Non-Operating Current Liabilities
11,8316,768
UIC License Agreement
82,78877,725
Other Non-Operating Current Liabilities
404,991404,991
Total long-term liabilities
416,822411,759
Total liabilities
9,570,7769,214,262
Stockholders’ equity (deficit):
Preferred Stock
00
Total Stockholders' Equity
2020
Total Stockholders' Equity
133,609,116132,484,015
Total Stockholders' Equity
(138,696,873)(132,379,849)
Total stockholders’ equity (deficit)
(5,087,737)104,186
Common Stock
2020
Additional Paid-in Capital
133,609,116132,484,015
Retained Earnings
(138,696,873)(132,379,849)
Total liabilities and stockholders’ equity (deficit)
4,483,0399,318,448
Actuate Therapeutics, Inc. (ACTU) — 10-Q Filing | Form 10 Explorer